Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease
Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease
复制标题
DOI：
10.1093/ibd/izaa241
复制
发表时间：
2021-07-01
影响因子：
4.9
通讯作者：
Minar, Phillip
中科院分区：
文献类型：
--
作者：
Colman, Ruben J.;Tsai, Yi-Ting;Minar, Phillip
背景资料：中性粒细胞粪便生物标志物钙卫蛋白（FCP）和乳铁蛋白（LCT）以及外周血中性粒细胞CD64表面受体（nCD64）是炎症性肠病（IBD）中粘膜炎症的生物标志物。尽管FCP已被评价为粘膜愈合的生物标志物，但LCT和nCD 64的临界点鲜为人知。我们的目的是确定与FCP缓解相关的LCT和nCD 64的临界点，次要目的是评估生化结果和英夫利西单抗（IFX）谷浓度之间的关系。方法：我们分析了在儿科克罗恩病（CD）队列研究中IFX诱导前后的FCP，LCT和nCD 64。第14周FCP生物标志物缓解定义为FCP
Background: The neutrophil fecal biomarkers, calprotectin (FCP) and lactoferrin (LCT), and peripheral blood neutrophil CD64 surface receptor (nCD64) are biomarkers for mucosal inflammation in inflammatory bowel disease (IBD). Although FCP has been evaluated as a biomarker for mucosal healing, cut points for LCT and nCD64 are less known. We aimed to identify the cut points for LCT and nCD64 that were associated with FCP remission, with a secondary aim to evaluate the relationship between biochemical outcomes and infliximab (IFX) trough concentrations.Methods: We analyzed FCP, LCT, and nCD64 before and after IFX induction in a pediatric Crohn's disease (CD) cohort study. Week-14 FCP biomarker remission was defined as FCP